PELDESINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H11N5O
Molecular Weight	241.2486
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC2=C(NC=C2CC3=CN=CC=C3)C(=O)N1

InChI

InChIKey=DOHVAKFYAHLCJP-UHFFFAOYSA-N

InChI=1S/C12H11N5O/c13-12-16-9-8(4-7-2-1-3-14-5-7)6-15-10(9)11(18)17-12/h1-3,5-6,15H,4H2,(H3,13,16,17,18)

HIDE SMILES / InChI

Molecular Formula	C12H11N5O
Molecular Weight	241.2486
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11369904 | https://clinicaltrials.gov/ct2/show/NCT00002237 | https://www.ncbi.nlm.nih.gov/pubmed/10828318

Peldesine (also known as BCX-34) was developed as a purine nucleoside phosphorylase (PNP) inhibitor. It is known PNP inhibitors may be useful for treating a variety of T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis, and Crohn s disease and T-cell cancers. Peldesine has undergone phase I trials for the treatment of human Immunodeficiency virus (HIV) infections. In addition, this drug participated in phase III clinical trial as a topical therapy for cutaneous T-cell lymphoma. This drug was also studied as a potential therapy for psoriasis, multiple sclerosis; rheumatoid arthritis; transplant rejection. However, all these indications were discontinued because of the lack of significant effects over placebo.

Approval Year

PubMed

Title	Date	PubMed
Case study: institutional review board (IRB) did not know about subject problem until after study.	2006-05	16832916
Biological activity of inorganic arsenic and antimony reflects oxidation state in cultured human keratinocytes.	2003-12	14680377
A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma.	2001-06	11369904
Evaluation of creams and ointments as suitable formulations for peldesine.	2001-05-21	11337167

Patents

Sample Use Guides

In Vivo Use Guide

peldesine (BCX-34) in a 1% dermal cream formulation. BCX-34 dermal cream 1% or the vehicle cream (as a placebo control) was applied twice daily to the entire skin surface for up to 24 weeks.

Route of Administration: Topical

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:35:54 GMT 2025` Edited by `admin` on `Mon Mar 31 21:35:54 GMT 2025`
Record UNII	7B646RJ70F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BCX-34

Preferred Name

English

PELDESINE

Official Name

English

4H-PYRROLO(3,2-D)PYRIMIDIN-4-ONE, 2-AMINO-3,5-DIHYDRO-7-(3-PYRIDINYLMETHYL)-

Systematic Name

English

Peldesine [WHO-DD]

Common Name

English

2-Amino-3,5-dihydro-7-(3-pyridylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one

Systematic Name

English

PELDESINE [USAN]

Common Name

English

peldesine [INN]

Common Name

English

PELDESINE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2151